3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
92
Melanoma
74
Squamous Cell Carcinoma of Head and Neck
47
Neoplasms
44
Neoplasm Metastasis
43
Lung Neoplasms
37
Carcinoma, Renal Cell
36
Colorectal Neoplasms
35
Breast Neoplasms
35
Triple Negative Breast Neoplasms
31
Stomach Neoplasms
26
Carcinoma, Transitional Cell
26
Ovarian Neoplasms
24
Head and Neck Neoplasms
24
Parkinson Disease 4, Autosomal Dominant Lewy Body
21
Esophageal Neoplasms
20
Pancreatic Neoplasms
18
Uterine Cervical Neoplasms
17
Urinary Bladder Neoplasms
16
Small Cell Lung Carcinoma
15
Endometrial Neoplasms
15
Carcinoma, Hepatocellular
15
Sarcoma
13
Recurrence
12
Glioblastoma
12
Carcinoma
12
Prostatic Neoplasms
11
Lymphoma
11
Mesothelioma
9
Carcinoma, Merkel Cell
9
Interventions
Cyclophosphamide
34
fludarabine phosphate
33
Cytarabine
33
fludarabine
26
Peripheral Blood Stem Cell Transplantation
23
Filgrastim
23
Methotrexate
18
Busulfan
17
Rituximab
15
Cyclosporine
14
Azacitidine
14
Melphalan
13
Clofarabine
13
Tacrolimus
12
venetoclax
11
Mycophenolic Acid
10
Etoposide
10
Alemtuzumab
10
Radiotherapy
9
Imatinib Mesylate
8
Granulocyte Colony-Stimulating Factor
8
Decitabine
8
ruxolitinib
7
Whole-Body Irradiation
7
Stem Cell Transplantation
7
Idarubicin
7
Dexamethasone
7
Antilymphocyte Serum
7
aldesleukin
6
Mitoxantrone
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Leukemia
×
pembrolizumab
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled